Abbott Buys StarLIMS for $123M to Strengthen Diagnostic Presence, Expand into New Markets | GenomeWeb

By Bernadette Toner

Abbott Laboratories announced this week that it will acquire StarLIMS Technologies for $123 million in a move designed to solidify its current presence in the diagnostic market while helping it expand into new sectors, such as forensics, microbiology, and public health.

Under the terms of the agreement, Abbott will acquire the 160-employee Tel Aviv, Israel-based laboratory informatics firm for $14 per share in an all-cash transaction valued at $123 million.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.